Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04360044 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Inhaled Cannabis for Acute Migraine Treatment
A Phase 2 study of Migraine and Cannabis, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT04360044 is a Phase 2 study of Migraine and Cannabis that has completed, run by University of California, San Diego. The registered enrollment target is 92 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04360044, a Phase 2 study of Migraine and Cannabis, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.
Interventions
- DRUG THC ~5%
- DRUG CBD ~12%
- DRUG THC ~5% and CBD ~12%
- DRUG Sham Cannabis
Study Locations (1)
California
- Center for Pain Medicine, UC San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2020-11-20 |
| Est. Completion | 2023-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04360044
The ClinicalTrials.gov registry entry for NCT04360044 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (74% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Migraine appearing as the primary indexed condition, and to 4 interventions - of which THC ~5% is the first listed.
NCT04360044 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04360044 about?
NCT04360044 is a clinical study titled "Efficacy of Inhaled Cannabis for Acute Migraine Treatment". This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.
What is the current status of trial NCT04360044?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2020-11-20. Estimated completion is 2023-02-23.
What conditions does trial NCT04360044 study?
This clinical trial studies the following conditions: Migraine, Cannabis, THC, CBD.
What interventions are being tested in trial NCT04360044?
The interventions under investigation include: THC ~5% (DRUG), CBD ~12% (DRUG), THC ~5% and CBD ~12% (DRUG), Sham Cannabis (DRUG).
Who is sponsoring clinical trial NCT04360044?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04360044 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
RECRUITING · Phase 2
-
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
RECRUITING · Phase 2
-
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.